-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Maintains Outperform on Pyxis Oncology, Lowers Price Target to $7

Benzinga·07/02/2026 12:34:55
Listen to the news
Leerink Partners analyst Jeffrey La Rosa maintains Pyxis Oncology (NASDAQ:PYXS) with a Outperform and lowers the price target from $9 to $7.